Sistemic cuts cost of drug discovery
Launches microRNA technology to filter out harmful compounds early in development process
Glasgow-based Sistemic has launched SistemTOX, an early predictive and investigative drug toxicity screening service that potentially could save millions of pounds in costs.
Based on microRNA research and technology, SistemTOX filters out potentially harmful compounds early in the development process.
Sistemic chief executive Professor Chris Hillier said: ‘Building on leading Scottish research expertise, SistemTOX uses microRNA profiling to decipher, early on, potential toxicity. Furthermore, it is not just a yes/no answer it also provides context which feeds important information quickly back to the scientists. Basically it places the power back into the developer’s hands and reduces risk.’